Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostically Challenging but Infrequent Aberrant Immunophenotypic Patterns in B-Lymphoblastic Leukemia/Lymphoma (B-ALL).

International journal of laboratory hematology·2025
Same author

Feed intake, milk production and feed conversion of dairy cows fed re-ensiled press cake from grass-clover silage compared to unprocessed grass-clover silage.

Archives of animal nutrition·2025
Same author

Coronary plaque vulnerability in statin-treated patients with elevated LDL-C and hs-CRP: optical coherence tomography study.

The international journal of cardiovascular imaging·2024
Same author

A Novel Bio-Purification Process Employing an Engineered <i>E. coli</i> Strain for Downstream Processing of Lactic Acid Solutions from the Fermentation of Agro-Industrial by-Products.

Bioengineering (Basel, Switzerland)·2024
Same author

Development of a hybrid bio-purification process of lactic acid solutions employing an engineered E. coli strain in a membrane bioreactor.

Biotechnology for biofuels and bioproducts·2024
Same author

Durable left ventricular assist device implant-how I teach it.

Indian journal of thoracic and cardiovascular surgery·2023

Related Experiment Video

Updated: May 25, 2026

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

Current status of additive solutions for platelets.

Hiba Alhumaidan1, Joseph Sweeney

  • 1The Miriam Hospital, Providence, Rhode Island 02906, USA.

Journal of Clinical Apheresis
|February 3, 2012
PubMed
Summary

Storing platelets in additive solutions (PAS) offers advantages over plasma storage, reducing allergic reactions and improving viability. Future platelet storage will likely utilize advanced PAS for extended shelf life and enhanced safety.

More Related Videos

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro
10:25

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro

Published on: March 19, 2016

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

Related Experiment Videos

Last Updated: May 25, 2026

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro
10:25

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro

Published on: March 19, 2016

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

Area of Science:

  • Blood banking and transfusion medicine
  • Platelet storage and preservation
  • Biomaterials and formulation science

Background:

  • Platelet storage in additive solutions (PAS) has historically lagged behind red blood cell concentrate storage, particularly in North America.
  • Current methods involve partial or complete removal of anticoagulated plasma for platelet concentrate storage in AS, presenting numerous benefits.
  • The formulation of PAS can be tailored to enhance aerobic metabolism or minimize platelet activation, thereby mitigating the platelet storage lesion and potentially boosting in vivo viability.

Purpose of the Study:

  • To explore the advantages of storing platelets in additive solutions (PAS) compared to traditional plasma storage.
  • To highlight the potential of PAS to abrogate the platelet storage lesion and improve post-transfusion viability.
  • To discuss the future direction of platelet storage, emphasizing advanced PAS formulations.

Main Methods:

  • Review of existing literature on platelet storage in additive solutions (AS) versus plasma.
  • Analysis of the impact of PAS formulation on platelet metabolism and activation.
  • Evaluation of the benefits of plasma removal, including reduced allergic reactions and plasma recovery.
  • Assessment of pathogen reduction technology in conjunction with PAS for platelet products.

Main Results:

  • Storage in PAS can be formulated to optimize platelet metabolism and reduce activation, mitigating storage lesion effects.
  • Plasma removal reduces allergic transfusion reactions and yields plasma for transfusion or fractionation.
  • PAS combined with pathogen reduction technology yields platelet products with hemostatic efficacy comparable to conventionally stored platelets.
  • PAS offers potential for extended shelf life and improved safety compared to plasma-stored platelets.

Conclusions:

  • Platelet storage in additive solutions (PAS) presents significant advantages, including improved viability and reduced adverse reactions.
  • Future advancements in platelet storage are expected to focus on novel, "designer" PAS formulations.
  • These next-generation PAS aim to provide extended shelf life and a superior safety profile compared to plasma-stored platelets.